Department of Psychology, Mary Free Bed Rehabilitation Hospital, Grand Rapids, MI, USA.
Clin Neuropsychol. 2020 Jan;34(1):56-87. doi: 10.1080/13854046.2019.1575471. Epub 2019 Apr 23.
: The purpose of this critical review was to evaluate the current state of research regarding the incremental value of neuropsychological assessment in clinical practice, above and beyond what can be accounted for on the basis of demographic, medical, and other diagnostic variables. The focus was on neurological and other medical conditions across the lifespan where there is known risk for presence or future development of cognitive impairment.: Eligible investigations were group studies that had been published after 01/01/2000 in English in peer-reviewed journals and that had used standardized neuropsychological measures and reported on objective outcome criterion variables. They were identified through PubMed and PsychInfo electronic databases on the basis of predefined specific selection criteria. Reference lists of identified articles were also reviewed to identify potential additional sources. The Grades of Recommendation, Assessment, Development and Evaluation Working Group's (GRADE) criteria were used to evaluate quality of studies.: Fifty-six studies met the final selection criteria, including 2 randomized-controlled trials, 9 prospective cohort studies, 12 retrospective cohort studies, 21 inception cohort studies, 2 case control studies, and 10 case series studies. The preponderance of the evidence was strongly supportive with regard to the incremental value of neuropsychological assessment in the care of persons with mild cognitive impairment/dementia and traumatic brain injury. Evidence was moderately supportive with regard to stroke, epilepsy, multiple sclerosis, and attention-deficit/hyperactivity disorder. Participation in neuropsychological evaluations was also associated with cost savings.: Neuropsychological assessment can improve both diagnostic classification and prediction of long-term daily-life outcomes in patients across the lifespan. Future high-quality prospective cohort studies and randomized-controlled trials are necessary to demonstrate more definitively the incremental value of neuropsychological assessment in the management of patients with various neurological and other medical conditions.
本综述的目的是评估神经心理学评估在临床实践中的应用价值,即除了基于人口统计学、医学和其他诊断变量之外,还能提供哪些额外的信息。重点关注的是在整个生命周期中存在认知障碍或未来发展风险的神经和其他医学疾病。
合格的研究为 2000 年 1 月 1 日之后以英文发表在同行评审期刊上的组研究,并使用了标准化的神经心理学测量方法,报告了客观的结果判断变量。通过 PubMed 和 PsychInfo 电子数据库,根据预先确定的具体选择标准进行了识别。还审查了已确定文章的参考文献列表,以确定潜在的其他来源。推荐、评估、制定和评估工作组 (GRADE) 的标准用于评估研究的质量。
56 项研究符合最终选择标准,包括 2 项随机对照试验、9 项前瞻性队列研究、12 项回顾性队列研究、21 项起始队列研究、2 项病例对照研究和 10 项病例系列研究。大量证据强烈支持神经心理学评估在轻度认知障碍/痴呆和创伤性脑损伤患者护理中的应用价值。证据表明,神经心理学评估在中风、癫痫、多发性硬化症和注意力缺陷多动障碍患者中的应用价值具有中等程度的支持。参与神经心理学评估也与成本节约有关。
神经心理学评估可以改善整个生命周期患者的诊断分类和长期日常生活结局的预测。未来需要高质量的前瞻性队列研究和随机对照试验来更明确地证明神经心理学评估在各种神经和其他医学疾病患者管理中的应用价值。